Business Description
Edwards Lifesciences Corp
NAICS : 339113
SIC : 3842
One Edwards Way, Irvine, CA, USA, 92614
Compare
Compare
Traded in other countries / regions
EWLS.Austria
•
E1WL34.Brazil
•
EWL.Germany
•
EW.Mexico
•
EW.Switzerland
•
0REN.UK
•
EW.USA
Description
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. Its key products include surgical tissue heart valves, transcatheter valve technologies, surgical clips, catheters, and monitoring systems used to measure a patient's heart function during surgery. The firm derives about 55% of its total sales from outside the U.S.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.22 | |||||
| Equity-to-Asset | 0.71 | |||||
| Debt-to-Equity | 0.12 | |||||
| Debt-to-EBITDA | 0.36 | |||||
| Interest Coverage | 2059 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 18.66 | |||||
| Beneish M-Score | -2.51 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 12.6 | |||||
| 3-Year EBITDA Growth Rate | 29.4 | |||||
| 3-Year EPS without NRI Growth Rate | 28.2 | |||||
| 3-Year FCF Growth Rate | 27.6 | |||||
| 3-Year Book Growth Rate | 22.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate Industry Rank | 12 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 10.58 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 67.95 | |||||
| 9-Day RSI | 63.8 | |||||
| 14-Day RSI | 61.64 | |||||
| 6-1 Month Momentum % | -12.67 | |||||
| 12-1 Month Momentum % | -14.65 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.37 | |||||
| Quick Ratio | 2.6 | |||||
| Cash Ratio | 1.56 | |||||
| Days Inventory | 226.66 | |||||
| Days Sales Outstanding | 42.21 | |||||
| Days Payable | 49.69 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.1 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 77.78 | |||||
| Operating Margin % | 30.76 | |||||
| Net Margin % | 27.18 | |||||
| ROE % | 25.71 | |||||
| ROA % | 17.68 | |||||
| ROIC % | 23.89 | |||||
| ROC (Joel Greenblatt) % | 76.02 | |||||
| ROCE % | 24.48 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 45.7 | |||||
| Forward PE Ratio | 41.63 | |||||
| PE Ratio without NRI | 45.7 | |||||
| Shiller PE Ratio | 74.73 | |||||
| Price-to-Owner-Earnings | 57.56 | |||||
| PEG Ratio | 3.41 | |||||
| PS Ratio | 12.41 | |||||
| PB Ratio | 11.02 | |||||
| Price-to-Tangible-Book | 14.68 | |||||
| Price-to-Free-Cash-Flow | 52.79 | |||||
| Price-to-Operating-Cash-Flow | 43.46 | |||||
| EV-to-EBIT | 36.29 | |||||
| EV-to-Forward-EBIT | 35.15 | |||||
| EV-to-EBITDA | 33.72 | |||||
| EV-to-Forward-EBITDA | 32.64 | |||||
| EV-to-Revenue | 12.08 | |||||
| EV-to-Forward-Revenue | 11.77 | |||||
| EV-to-FCF | 51.52 | |||||
| Price-to-Projected-FCF | 3.93 | |||||
| Price-to-DCF (Earnings Based) | 1.44 | |||||
| Price-to-DCF (FCF Based) | 1.72 | |||||
| Price-to-Median-PS-Value | 1.49 | |||||
| Price-to-Peter-Lynch-Fair-Value | 3.78 | |||||
| Price-to-Graham-Number | 5.45 | |||||
| Price-to-Net-Current-Asset-Value | 83.6 | |||||
| Earnings Yield (Greenblatt) % | 2.75 | |||||
| Forward Rate of Return (Yacktman) % | 13.44 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NYSE:EW
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 5,355 | ||
| EPS (TTM) ($) | 2.31 | ||
| Beta | 1.22 | ||
| Volatility % | 34.14 | ||
| 14-Day RSI | 61.64 | ||
| 14-Day ATR ($) | 3.096943 | ||
| 20-Day SMA ($) | 101.2905 | ||
| 12-1 Month Momentum % | -14.65 | ||
| 52-Week Range ($) | 85.58 - 131.73 | ||
| Shares Outstanding (Mil) | 619.94 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Edwards Lifesciences Corp Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||